Determine the effect of multiple doses of AZD7325, CYP Study - CYP
Study identifier:D1140C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase I open-labeled, fixed sequence study to determine the effect of multiple doses of AZD7325 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2)
Medical condition
Healthy Volunteer
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD7325, Midazolam, Caffeine
Sex
Male
Actual Enrollment
24
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Jul 2008
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD7325 Oral, day 1-12 Drug: Midazolam single dose, twice during treatment Drug: Caffeine single dose, twice during treatment |
Contacts
Investigators
Principal Investigator
Darren Wilbraham
Guy’s Drug Research Unit Quintiles
